Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 34, Suppl. 1, 2005
Issue release date: February 2005
Section title: Paper
Pathophysiol Haemost Thromb 2005;34:10–17

Ximelagatran in Orthopaedic Surgery

Eriksson B.
Department of Orthopedics, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden
email Corresponding Author

Dr. Bengt Eriksson

Department of Orthopedics

Sahlgrenska University Hospital/Östra

SE–41685 Gothenburg (Sweden)

Tel. +46 31 343 4408, Fax +46 31 343 4092, E-Mail b.eriksson@orthop.gu.se


  1. White RH: The epidemiology of venous thromboembolism. Circulation 2003;107:I4–I8.
    External Resources
  2. White RH, Zhou H, Romano PS: Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446–455.
  3. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB: Prevention of venous thromboembolism. Chest 2001;119:132S–175S.
    External Resources
  4. Iorio A, Agnelli G: Pharmacokinetic optimisation of the treatment of deep vein thrombosis. Clin Pharmacokinet 1997;32:145–172.
  5. Haycraft JB: On the action of a secretion obtained from the medicinal leech on the coagulation of the blood. Proc R Soc London 1884;36:478–487.
  6. Shionoya T: Studies in experimental extracorporeal thrombosis. III. Effects of certain anticoagulants (heparin and hirudin) on extracorporeal thrombosis and on the mechanisms of thrombosis. J Exp Med 1927;49:19–26.
    External Resources
  7. Riehl-Bellon N, Carvallo D, Acker M, Van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C: Purification and biochemical characterization of recombinant hirudin produced by Saccha romyces cerevisiae. Biochemistry 1989;28:2941–2949.
  8. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW: Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095–7101.
  9. Fitzgerald D, Murphy N: Argatroban: A synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455–458.
  10. Bajusz S: Chemistry and biology of the peptide anticoagulant D-MePhe-Pro-Arg-H (GYKI-14766). Adv Exp Med Biol 1993;340:91–108.
  11. Weitz JI: A novel approach to thrombin inhibition. Thromb Res 2003;109(suppl 1):S17–S22.
    External Resources
  12. Eriksson BI, Wille-Jørgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: A comparison of recombinant hirudin with a low- molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329–1335.
  13. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström JE, Eriksson U, Bredberg U, Teger-Nilsson AC: A new oral anticoagulant: The 50-year challenge. Nat Rev Drug Discov 2004;3:1–11.
    External Resources
  14. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D: Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294–305.
  15. Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial. Lancet 2002;360:1441–1447.
  16. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288–296.
  17. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: The EXPRESS study. J Thromb Haemost 2003;1:2490–2496.
  18. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW Jr: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648–655.
  19. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703–1712.
  20. Raskob GE, Hirsh J: Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003;124:379S–385S.
  21. Dahl OE, Bergqvist D: Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 2002;8:394–397.
  22. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R: Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2199–2207.
  23. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P, Close P: Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326–333.
  24. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P: Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635–639.
  25. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P: Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72:227–231.
  26. Eriksson BI, Dahl OE: Prevention of venous thromboembolism following orthopaedic surgery: Clinical potential of direct thrombin inhibitors. Drugs 2004;64:577–595.
  27. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D: Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002;87:300–305.
  28. Eikelboom JW, Quinlan DJ, Douketis JD: Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials. Lancet 2001;358:9–15.
  29. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE: Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann Intern Med 2001;135:858–869.